Newsroom

Learn more about Recolony bacteria-based cancer therapy, plus never miss an event.

Sep 9
1 min

Recolony among the Top100 Swiss Startups

Recolony enters the prestigious Top100 Swiss Startups ranking as newcomer in its first year of existence. The TOP 100 Swiss Startup Award...

Apr 20
1 min

Recolony gets featured by Handelzeitung

Philipp Busenhart, CBO of Recolony, presents our company in this interview with the Handelzeitung

Feb 23
1 min

Recolony receives CHF 150,000 from Venture Kick

Recolony wins the Stage III of Venture Kick. Recolony will invest the CHF 150,000 awarded by Venture Kick to advance our small molecule...

Feb 23
1 min

Recolony nominated as "Newcomer of the year"

Recolony has been nominated as Newcomer of the Year (Startup) by Viktor- The Swiss Healthcare Awards. Five Swiss startups have been...

Dec 2, 2022
1 min

Recolony selected as one of the Hello Tomorrow Deep Tech Pioneers!

We’ve been named one of Hello Tomorrow's Deep Tech Pioneers! Come and meet us at the Hello Tomorrow Global Summit 2023, March 9-10th in...

Nov 29, 2022
1 min

Recolony gets support from InnoBooster

The InnoBooster program from Gebert Rüf Stiftung aims at speeding up innovative, science-based deep tech businesses which have already...

Sep 15, 2022
1 min

SWICA interviews Recolony

SWICA September Newsletter includes an article about Recolony Source: Swiss.ch

Sep 12, 2022
0 min

Recolony gets featured in 20 Minutes newspaper

Jul 25, 2022
1 min

Recolony is selected for Venture Leaders Biotech

Recolony has been selected to be part of the Swiss National Startup Team 2022 and will join Venture Leaders Biotech next September in...

Jul 25, 2022
1 min

Recolony wins Venture Kick Stage II

Recolony wins Venture Kick Stage II and receives additional 40.000 CHF to support the development of our bacteria-based cancer therapy....

May 5, 2022
1 min

Recolony gets the Kick!

Recolony has successfully get into the Stage I of Venture Kick About Venture Kick: Venture Kick is a philanthropic three stage funding...

Apr 22, 2022
1 min

Our CEO is highlighted in the UZH Annual Report 2021

Ana Montalban-Arques got interviewed by the University of Zurich to talk about our bacteria-based cancer therapy for the treatment of...

Apr 14, 2022
1 min

We are finalists of >>venture>>, Switzerlands leading startup competition

Recolony was chosen as finalist in the >>venture>> startup competition. On the 19th of May we will pitch in the final and compete against...

Apr 13, 2022
1 min

We are part of the Swiss Microbiomes Forum

Recolony is selected to participate in the pitching competition during the Swiss Microbiomes Forum organized by NCCR Microbiomes, the 6th...

Apr 12, 2022
1 min

Pharmabiotics Conference 2022

Come and hear our CEO Ana Montalban-Arques , speak about "Commensal Bacteria as Stand-alone Therapy for Colorectal Cancer". About the...

Mar 24, 2022
1 min

Recolony raises 200.000 CHF from the USZ Health Innovation Hub

Recolony receives support from the USZ Health Innovation Hub to advance their bacteria-based cancer therapy. The Health Innovation Hub is...

Feb 11, 2022
1 min

Our CEO wins a young women scientist award

Our CEO Ana Montalban-Arques is awarded with one of the Lyceum Awards to young women scientists in the category of Health Sciences. She...

Jan 25, 2022
1 min

Werner Siemens Stiftung interviews Ana Montalban-Arques

Within the section "From lab to market" of the Werner Siemens Stiftung annual report 2021, our CEO Ana Montalban-Arques explains the...

Nov 7, 2021
1 min

Our CEO wins the Falling Walls Breakthrough of Year in the Emerging Talents Category

Ana Montalban-Arques wins the Breakthrough of the Year in the Emerging Talents Category with the presentation “Breaking the Wall of...

Oct 15, 2021
1 min

Our research gets featured in Cell Reports Medicine.

Our article "Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors" is highlighted in the...

Sep 28, 2021
1 min

Ana Montalban-Arques wins Falling Walls Lab Switzerland

With the presentation entitled “Breaking the Wall of Ineffective Cancer Therapies” Ana won the 1st place in the competition and the...

Dec 10, 2020
1 min

Ana Montalban-Arques receives support from the BRIDGE programme.

The project "Selected Clostridiales bacteria as novel treatment for solid tumors" has been awarded with the BRIDGE Proof of Concept...

Jun 8, 2020
1 min

Ana Montalban-Arques receives 150.000CHF from the UZH Entrepreneur Fellowship

With the fellowship Ana Montalban-Arques will develop a formulation of a more storage-stable, lyophilized bacteria and test the efficacy,...